Our geographic presence is extensive, covering more than 100 countries.

Our global reach

Since 2008, we have been adapting our business to capitalise on the higher growth potential of markets outside Europe and the USA. These territories now account for 40% of our total sales. At the same time, we have reshaped our western business to reflect the challenging commercial environment.

We have a significant manufacturing and R&D presence with a network of 87 manufacturing sites and large R&D centres in the UK, USA, Spain, Belgium and China.

 

Turnover by region:
USA	£8.4 billion
Europe	£7.3 billion
EMAP	£6.8 billion
Japan	£2.2 billion
Other	£1.6 billion

How we are structured

Our commercial businesses are structured around regional units or areas of focus.

For our Pharmaceuticals and Vaccines businesses, we operate with segments that combine these areas.  Our Consumer Healthcare business functions as a global unit, as does ViiV Healthcare, the specialist HIV company we founded with Pfizer in 2009.

Other trading turnover includes Canada, Puerto Rico, central vaccine tender sales and contract manufacturing sales.

 

Turnover by segment:
US Pharmaceutical and Vaccines	£7.0 billion
Europe Pharmaceutical and Vaccines	£5.0 billion
Emerging Markets Pharmaceutical and Vaccines	£4.7 billion
Japan Pharmaceutical and Vaccines	£2.0 billion
ViiV Healthcare	£1.4 billion
Other trading	£1.2 billion
Consumer Healthcare	£5.1 billion